Close Menu

Cepheid

The paper, which is not peer-reviewed, said that use of the test as a first-step screening tool would require confirmation of more than 80 percent of its results.

Danaher President and CEO Thomas Joyce will retire in September and will be replaced by Rainer Blair, the current executive VP of the life sciences division.

Missed Ones

An analysis by Cleveland Clinic researchers finds some SARS-CoV-2 tests have a high false negative rate, NPR reports.

The new rate applies to clinical diagnostic lab tests using high-throughput technologies that can process more than 200 specimens per day.

Bringing testing closer to patients could be helpful, provided enough tests and instruments can be manufactured and distributed.

Cepheid's Xpert Xpress SARS-CoV-2 rapid molecular diagnostic test can be used in high- and moderate-complexity labs and at the point of care in certain settings.

The Economist writes that two kinds of testing are important to control the spread of COVID-19.

The deal is part of a wider collaboration between the companies to develop molecular diagnostic tests using their respective platforms.

A recent study established high sensitivity and specificity for three CLIA waived point-of-care molecular flu tests in pediatric samples.

A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.